Northern Institute for Cancer Research


Childhood Leukaemia

Our research identifies genetic abnormalities, which guides the best treatment options for our patients. We explore the mechanisms underlying leukaemia development and persistence. We develop novel treatments to improve survival and quality of life.

Bill Bryson visiting one of our labs.
Bill Bryson visiting one of our labs.


Approximately 500 children and adolescents are diagnosed with leukaemia in the UK each year.

Despite the high cure rate, leukaemia remains one of the leading causes of death in children with cancer. Eight out of 10 of children are cured, but in the remainder the disease recurs, with less chance of survival.

Current treatment protocols are responsible for the high cure rate, but there are substantial side effects. These occur both during and long after treatment.

This indicates the need to search for alternative therapies.

Our research

We define patients into subgroups based on their genetic profile. This aims to guide the most appropriate treatment.

We have translated several discoveries into clinical practice which have been adopted in the UK and worldwide. These have been instrumental in improving the survival of patients with leukaemia.

We study how genetic changes arise, and how they drive the development and maintenance of leukaemia.

We translate these findings into novel therapeutic concepts. These are tested in our ground-breaking experimental systems.

Research groups